A comparison of clinically relevant sources of mesenchymal stem cell-derived exosomes: Bone marrow and amniotic fluid
jpedsurg.org shows its articles on its own site.
Read the article on jpedsurg.org ↗Article · Oct 2018 · 1 min read
In brief
In brief
Comparative study of exosomes derived from bone marrow and amniotic fluid mesenchymal stem cells for potential cell-free therapeutic applications in perinatal and pediatric diseases. Amniotic fluid MSCs yielded 25% more exosomes than bone marrow MSCs with comparable surface marker expression, suggesting amniotic fluid may be a superior source for exosome-based therapies.
Written by the GCMD Library team from the article.
Background/Purpose
Exosomes may constitute a more practical alternative to live cells in select stem cell-based therapies. We sought to compare exosomes from two mesenchymal stem cell (MSC) sources relevant to perinatal and pediatric diseases.
Methods
Exosomes were isolated by reagent-enhanced centrifugation from cell culture media of banked human bone marrow (bm) and amniotic fluid (af) MSCs after serum starvation. Characterization was by flow exometry for tetraspanin markers CD9, CD63, and CD81, transmission electron microscopy for size and morphology, and tunable resistive pulse sensing for size distribution and concentration. Statistical comparisons of count data were made by Poisson regression modeling and Student's T-test.
Results
Exosomes of appropriate size and morphology were isolated with comparable expressions of CD9 (96% vs. 94%), CD63 (88% vs. 66%), and CD81 (71% vs. 63%) for bmMSC and afMSC, respectively. Total exosome yield (particles/mL) adjusted for number of cells was higher from afMSCs than bmMSCs by an estimated 25% (P